Published

European agency for rare diseases may approve a new drug for Alzheimer's disease.

Summary by aktuality.sk
The risks of side effects of the drug returning possible bleeding into the brain outweigh its benefits, according to the agency.
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.